Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 479

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 479
---
 the same period that the related

F-2

revenue is recognized and creates variability for the consideration that the Company expects to receive. Liabilities related to government rebates and chargebacks involve the use of assumptions and judgments that include consideration of historical claims experience and channel mix. We identified management’s estimated allowance for government rebates and chargebacks as a critical audit matter. The principal consideration that led to our determination is the judgment required to estimate government rebates and chargebacks that will be processed based upon the experience to date. Auditing these elements involved challenging auditor judgment due to the nature and extent of audit effort required to address these matters. The primary procedures we performed to address this critical audit matter included:

| • |     | Developing an independent estimate of the allowance for government rebates and chargebacks by utilizing product                                                                                                   
 sales, the historical trend of actual rebates and chargebacks claims paid; (ii) comparing the independent estimate to management’s estimate; and (iii) testing historical rebate and chargebacks claims received. |

/s/ BDO USA, P.C. We have served as the Company’s auditor since 2017 San Diego, California March 13, 2024 F-3

AADI BIOSCIENCE, INC. Consolidated Balance Sheets (in thousands, except share data and par value)

|                                                                                                    |     | Year Ended December 31, |     2023 |   |     |   |     2022 |   |
|:---------------------------------------------------------------------------------------------------|:----|:------------------------|---------:|:--|:----|:--|---------:|:--|
| Current assets:                                                                                    |     |                         |          |   |     |   |          |   |
| Cash and cash equivalents                                                                          |     | $                       |   62,888 |   |     | $ |   39,019 |   |
| Short-term investments                                                                             |     |                         |   45,957 |   |     |   |  133,541 |   |
| Accounts receivable, net                                                                           |     |                         |    5,488 |   |     |   |    1,862 |   |
| Inventory                                                                                          |     |                         |    6,427 |   |     |   |    1,861 |   |
| Prepaid expenses and other current assets                                                          |     |                         |    3,826 |   |     |   |    3,746 |   |
| Total current assets